# EDGAR Filing Document

**Accession Number:** 0000920148
**File Stem:** 0000920148-25-000111
**Filing Date:** 2025-11
**Character Count:** 11599
**Document Hash:** b67d16e100b5cb505bd56b7fffef3f67
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000920148-25-000111.hdr.sgml**: 20251124

**ACCESSION NUMBER**: 0000920148-25-000111

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251124

**DATE AS OF CHANGE**: 20251124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LABCORP HOLDINGS INC.
- **CENTRAL INDEX KEY:** 0000920148
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 992588107
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11353
- **FILM NUMBER:** 251509671

**BUSINESS ADDRESS:**
- **STREET 1:** 358 S MAIN ST
- **CITY:** BURLINGTON
- **STATE:** NC
- **ZIP:** 27215
- **BUSINESS PHONE:** 3362291127

**MAIL ADDRESS:**
- **STREET 1:** 358 S MAIN ST
- **CITY:** BURLINGTON
- **STATE:** NC
- **ZIP:** 27215

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LABORATORY CORP OF AMERICA HOLDINGS
- **DATE OF NAME CHANGE:** 19950504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NATIONAL HEALTH LABORATORIES HOLDINGS INC
- **DATE OF NAME CHANGE:** 19940314

?xml version='1.0' encoding='ASCII'? lh-20251120

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

<u>November 20, 2025</u>

(Date of earliest event reported)

**LABCORP HOLDINGS INC.** 

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-11353** | **99-2588107** |
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | | | |
|:---|:---|:---|:---|
| **358 South Main Street** | **358 South Main Street** | **358 South Main Street** | |
| **Burlington** | **,** | **North Carolina** | **27215** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip Code) |

---

(Registrant's telephone number including area code) **336-229-1127** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of exchange on which registered** |
| Common Stock, $0.10 par value | LH | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |
| Labcorp Holdings Inc. (the "Company") today announced that on November 20, 2025, the Company's Board of Directors (the "Board") appointed Victor Bulto as a member of the Board, effective December 1, 2025. Mr. Bulto will be entitled to receive compensation for his service on the Board consistent with the Company's director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025.<br>Mr. Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, serving in each role since April 2022. In his more than two decades of experience at Novartis, Mr. Bulto has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. Mr. Bulto holds a Master's in Health Economics and Pharmacoeconomics and a Postgraduate Degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. Mr. Bulto earned his MBA from ESADE Business School, Spain and completed the Advanced Management Program at Harvard Business School. He also holds a Master's in Chemical Engineering and a Bachelor of Science in Chemistry from Institut Químic de Sarrià in Spain. | Labcorp Holdings Inc. (the "Company") today announced that on November 20, 2025, the Company's Board of Directors (the "Board") appointed Victor Bulto as a member of the Board, effective December 1, 2025. Mr. Bulto will be entitled to receive compensation for his service on the Board consistent with the Company's director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025.<br>Mr. Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, serving in each role since April 2022. In his more than two decades of experience at Novartis, Mr. Bulto has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. Mr. Bulto holds a Master's in Health Economics and Pharmacoeconomics and a Postgraduate Degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. Mr. Bulto earned his MBA from ESADE Business School, Spain and completed the Advanced Management Program at Harvard Business School. He also holds a Master's in Chemical Engineering and a Bachelor of Science in Chemistry from Institut Químic de Sarrià in Spain. |
| **Item 7.01** | **Regulation FD Disclosure.** |
| On November 24, 2025, the Company issued a press release announcing the appointment of Mr. Bulto to the Board. A copy of that press release is attached to, and incorporated by reference into, this current report as Exhibit 99.1. | On November 24, 2025, the Company issued a press release announcing the appointment of Mr. Bulto to the Board. A copy of that press release is attached to, and incorporated by reference into, this current report as Exhibit 99.1. |

---

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |
| <u>Exhibit</u> | <u>Exhibit Name</u> |
| Exhibit 99.1 | <u>[Press Release dated November 24, 2025 issued by the Compan](formpr112425ex991boardmemb.htm)[y](formpr112425ex991boardmemb.htm)</u> |
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>LABCORP HOLDINGS INC.</u>

Registrant

---

| | | |
|:---|:---|:---|
| Date: November 24, 2025 | By: | /s/ SANDRA D. VAN DER VAART |
|  |  | Sandra D. van der Vaart |
|  |  | Executive Vice President, Chief Legal Officer and Corporate Secretary |

---

## Exhibit 99.1

![lc2020logov2.gif](lc2020logov2.gif)

**<u>FOR IMMEDIATE RELEASE</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

---

| |
|:---|
| **Contact:** |
| **Neil Hirsch - Media** |
| **Media@labcorp.com** |
| **Christin O'Donnell - Investors** |
| **Investor@labcorp.com** |

---

**Labcorp Appoints Victor Bulto to Board of Directors**

**Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy**

BURLINGTON, N.C., November 24, 2025 -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.

Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leading large, complex organizations across the U.S. and Europe. He currently oversees Novartis' U.S. business—a $20+ billion operation—with responsibility across four key therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic.

Throughout his career at Novartis, Bulto has shaped bold strategies and delivered commercial excellence, enabling businesses to stay ahead amid intensifying regulatory and market pressures. He brings deep expertise in transformation, harnessing technology and automation to simplify processes, drive efficiency, and build future-ready operating models. By anticipating opportunities and building toward them, he drives progress at the evolving intersection of healthcare innovation and consumer expectations, creating new pathways for patient-centered care.

"Victor's appointment to our Board underscores Labcorp's focus on long-term growth through innovation and global healthcare leadership," said Adam Schechter, Chairman and Chief Executive Officer of Labcorp. "His experience leading one of the largest pharmaceutical businesses in the U.S., combined with his expertise across key therapeutic areas, will be invaluable as we advance our strategic priorities and focus on innovating through science and technology to deliver greater value for our customers and shareholders."

"I deeply believe in Labcorp's mission and am honored to join the Board at a time of industry growth and medical advancement, particularly in the field of precision medicine," said Bulto. "Labcorp's scale and infrastructure, combined with its commitment to meaningful patient impact, create a unique opportunity to accelerate access to novel therapies and shape the future of healthcare."

------

**About Labcorp** 

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.